000008350 001__ 8350
000008350 005__ 20240819142530.0
000008350 022__ $$a0264-410X
000008350 0247_ $$2DOI$$a10.1016/j.vaccine.2017.10.108
000008350 037__ $$aARTICLE
000008350 039_9 $$a2024-08-19 14:25:30$$b1$$c2023-09-05 15:24:44$$d1$$c2021-12-17 15:25:31$$d0$$c2021-11-17 11:26:48$$d1001252$$c2021-09-02 23:38:18$$d0$$c2021-09-02 09:49:21$$d1000944$$c2021-09-02 09:48:34$$d1000944$$c2021-08-26 13:18:32$$d0$$y2021-08-26 13:18:26$$z1000944
000008350 041__ $$aeng
000008350 245__ $$aInnovative vaccine delivery strategies in response to a cholera outbreak in the challenging context of Lake Chilwa :$$ba rapid qualitative assessment
000008350 269__ $$a2018-10
000008350 300__ $$a6 p.
000008350 500__ $$aDémolis, Rachel est chercheuse à la HES-SO, HESAV, depuis 2018.
000008350 506__ $$avisible
000008350 520__ $$9eng$$aA reactive campaign using two doses of Shanchol Oral Cholera Vaccine (OCV) was implemented in 2016 in the Lake Chilwa Region (Malawi) targeting fish dependent communities. Three strategies for the second vaccine dose delivery (including delivery by a community leader and self-administration) were used to facilitate vaccine access. This assessment collected vaccine perceptions and opinions about the OCV campaign of 313 study participants, including: fishermen, fish traders, farmers, community leaders, and one health and one NGO officer. Socio-demographic surveys were conducted, In Depth Interviews and Focus Group Discussions were conducted before and during the campaign. Some fishermen perceived the traditional delivery strategy as reliable but less practical. Delivery by traditional leaders was acceptable for some participants while others worried about traditional leaders not being trained to deliver vaccines or beneficiaries taking doses on their own. A slight majority of beneficiaries considered the self-administration strategy practical while some beneficiaries worried about storing vials outside of the cold chain or losing vials. During the campaign, a majority of participants preferred receiving oral vaccines instead of injections given ease of intake and lack of pain. OCV was perceived as efficacious and safe. However, a lack of information on how sero-protection may be delayed and the degree of sero-protection led to loss of trust in vaccine potency among some participants who witnessed cholera cases among vaccinated individuals. OCV campaign implementation requires accompanying communication on protective levels, less than 100% vaccine efficacy, delays in onset of sero-protection, and out of cold chain storage.
000008350 540__ $$aincorrect
000008350 592__ $$aHESAV
000008350 592__ $$bAucun institut
000008350 592__ $$cSanté
000008350 6531_ $$9eng$$acholera vaccines
000008350 6531_ $$9eng$$aself administration
000008350 6531_ $$9eng$$afishermen
000008350 6531_ $$9eng$$avulnerable population
000008350 6531_ $$9eng$$aattitude to health
000008350 6531_ $$9eng$$aanthropology
000008350 655__ $$ascientifique
000008350 700__ $$aHeyerdahl, Leonard W.$$uAgence de Médecine Préventive, Abidjan, Cote d'Ivoire
000008350 700__ $$aNgwira, Bagrey$$uUniversity of Malawi, College of Medicine, Community Health Department, Blantyre, Malawi
000008350 700__ $$aDémolis, Rachel$$uAgence de Médecine Préventive, Ferney-Voltaire, France
000008350 700__ $$aGabriel, Nyirenda$$uUniversity of Malawi, College of Medicine, Community Health Department, Blantyre, Malawi
000008350 700__ $$aMwesawina, Maurice$$uMinistry of Health Malawi, Lilongwe, Malawi
000008350 700__ $$aRafael, Florentina$$uAgence de Médecine Préventive, Abidjan, Cote d'Ivoire
000008350 700__ $$aCavailler, Philippe$$uAgence de Médecine Préventive, Ferney-Voltaire, France
000008350 700__ $$aGargasson, Jean Bernard Le$$uAgence de Médecine Préventive, Ferney-Voltaire, France
000008350 700__ $$aMengel, Martin A.$$uAgence de Médecine Préventive, Paris, France
000008350 700__ $$aGessner, Bradford D.$$uAgence de Médecine Préventive, Paris, France
000008350 700__ $$aGuillermet, Elise$$uAgence de Médecine Préventive, Ferney-Voltaire, France
000008350 773__ $$jOctober 2018, vo. 36, no. 44, pp. 6491-6496$$tVaccine
000008350 8564_ $$s386064$$uhttps://arodes.hes-so.ch/record/8350/files/Published%20version.pdf$$9871c8613-0cce-4914-991c-c416e226acee
000008350 906__ $$aGOLD
000008350 909CO $$ooai:hesso.tind.io:8350$$pGLOBAL_SET
000008350 950__ $$aaucun
000008350 980__ $$ascientifique
000008350 981__ $$ascientifique